ClinicalTrials.gg
TerminatedNCT02920242Updated Mar 25, 2019Results posted

A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.

A Phase 3 interventional study of Rifaximin (Sandoz GmbH) tablet and Rifaximin (Xifaxan) in Travelers' Diarrhea, sponsored by Sandoz. Terminated at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-25.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated due to low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.

Enrollment
18th of 19
28 · median 210
Started
2016
with 1 other
Phase 3
10 of 19
none open now
Registered
14th of 19
by date
Lead sponsor
1 of 19
Sandoz

Among the 19 studies testing rifaximin in Diarrhea, this one is the 18th largest by enrollment, is one of 2 that started in 2016, is one of 10 in phase 3, and was the 14th registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing rifaximin in Diarrhea, or all of them as a file.
02

Study summary

This study compared safety and efficacy of a generic rifaximin tablet to the reference listed drug in the treatment of travelers' diarrhea. Additionally both the generic and reference formulations were tested for superiority against a placebo tablet.

It was planned that 450 patients would be enrolled, but only 28 patients were randomized. Of these, 1 patient discontinued due to failure to meet the inclusion/exclusion criteria. The remaining 27 patients received study drug and 25 patients completed the study.

The study was terminated due to slow enrolment. The final analysis included only safety analysis in the Safety population, due to the low number of randomized patients. No efficacy analysis was performed.

03

Conditions studied

  • Travelers' Diarrhea

Browse trials for

Keywords

  • Travelers
  • diarrhea
  • rifaximin
  • equivalence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is able to read and understood the language of the Form and Patient Information.
  • International travelers with a duration of stay in host country long enough to attend schedules visits.
  • Affected by naturally acquired acute diarrhea, defined as the passage of at least 3 unformed stools within 24 hours immediately preceding randomization preceding randomization

Exclusion criteria

Exclusion Criteria:

  • to rifaximin or any of the rifamycin antimicrobial agents or to any of the of the study drug.
  • Pregnant, breast feeding or planning pregnancy
  • Acute diarrhea for > 72 hours immediately prior to randomization.
  • Presence of fever (≥ 100 °F/37.8°C) or hematochezia (blood in stool, noted visually) or clinical findings suggesting moderate or severe dehydration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Rifaximin

    Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.

    Drug: Rifaximin (Sandoz GmbH) tablet

  • Active comparator
    Xifaxan

    Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.

    Drug: Rifaximin (Xifaxan)

  • Placebo comparator
    Placebo

    Patients received placebo tablet 3 times per day for 3 days.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Cure Rate

    Clinical cure was defined as either no stools or only formed stools within a 48 hour period and no fever, with or without other enteric symptoms, OR no watery stools or no more than two soft stools passed within a 24 hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence.

    Time frame: study day 5 +/- 1 day

Secondary outcomes

  1. Time to Last Unformed Stool

    Time frame: within 5 study days

  2. Proportion of Patients With Clinical Failure

    Time frame: within 5 study days

  3. Proportion of Patients With Improvement of Diarrheal Syndrome

    Time frame: within 5 study days

  4. Number of Unformed Stools

    Time frame: within 5 study days

  5. The Presence or Absence and Severity of Signs and Symptoms of Enteric Infection

    Time frame: within 5 study days

  6. Microbiological Cure Rate

    Time frame: study day 5

07

Results

Posted Mar 25, 2019

Participant flow

Participant flow — Overall Study
MilestoneRifaximinXifaxanPlacebo
Started13114
Safety set12114
Completed11113
Not completed201
Withdrew: Withdrawal by subject101
Withdrew: Did not meet inc./exc. criteria100

Outcome measures

PrimaryClinical Cure Rate

Clinical cure was defined as either no stools or only formed stools within a 48 hour period and no fever, with or without other enteric symptoms, OR no watery stools or no more than two soft stools passed within a 24 hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence.

Time frame:
study day 5 +/- 1 day

No measurements were reported for this outcome.

SecondaryTime to Last Unformed Stool
Time frame:
within 5 study days

No measurements were reported for this outcome.

SecondaryProportion of Patients With Clinical Failure
Time frame:
within 5 study days

No measurements were reported for this outcome.

SecondaryProportion of Patients With Improvement of Diarrheal Syndrome
Time frame:
within 5 study days

No measurements were reported for this outcome.

SecondaryNumber of Unformed Stools
Time frame:
within 5 study days

No measurements were reported for this outcome.

SecondaryThe Presence or Absence and Severity of Signs and Symptoms of Enteric Infection
Time frame:
within 5 study days

No measurements were reported for this outcome.

SecondaryMicrobiological Cure Rate
Time frame:
study day 5

No measurements were reported for this outcome.

Adverse events

Collected over up to day 5 +/- 1 day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rifaximin0/12 (0%)0/12 (0%)2/12 (16.7%)
Xifaxan0/11 (0%)0/11 (0%)5/11 (45.5%)
Placebo0/4 (0%)0/4 (0%)0/4 (0%)
Most frequent other events
Most frequent other events
EventRifaximinXifaxanPlacebo
HeadacheNervous system disorders1/123/110/4
DizzinessNervous system disorders0/122/110/4
Lacrimation increasedEye disorders0/121/110/4
Abdominal pain upperGastrointestinal disorders0/121/110/4
Medication errorInjury, poisoning and procedural complications0/121/110/4
ConstipationGastrointestinal disorders1/120/110/4

Baseline characteristics

Baseline characteristics was based on the safety analysis set.

Age, Continuous
Age, Continuous(Years)RifaximinXifaxanPlaceboTotal
Mean36.3 ± 18.2738.2 ± 18.6935.8 ± 21.9337.0 ± 18.22
Sex: Female, Male
Sex: Female, Male(Participants)RifaximinXifaxanPlaceboTotal
Female57113
Male74314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RifaximinXifaxanPlaceboTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White1111426
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Sandoz Investigative Site
    Mexico City, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in May 2017, 5 months.

Results were first posted in Mar 2019, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2016
First posted
Sep 30, 2016
StartActual
Dec 15, 2016
Primary completionActual
May 23, 2017
CompletionActual
May 23, 2017
Results first posted
Mar 25, 2019
Last update
Mar 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02920242
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Sep 30, 2016
Start date
Dec 15, 2016
Primary completion
May 23, 2017
Completion
May 23, 2017
Results posted
Mar 25, 2019
Last update
Mar 25, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion